drugset

drugset / Trial / NCT03201627

Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease

NCT03201627 ↗

Phase 0 Unknown 18 enrolled Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is planned to study whether lithium carbonate has protective effect on the brain of Niemann-Pick disease type C1.

Timeline

Start: 2017-07-05
Primary completion: 2020-09-30
Completion: 2021-06-30

Publications

Han S, Zhang H, Yi M, Liu X, Maegawa GHB, Zou Y, Wang Q, Wu D, Ye Z. Potential Disease-Modifying Effects of Lithium Carbonate in Niemann-Pick Disease, Type C1. Front Pharmacol. 2021 Jun 9;12:667361. doi: 10.3389/fphar.2021.667361. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lithium Carbonate	Unknown	300 mg	Oral
Subject	Lithium Carbonate	Unknown	600 mg	Oral
Subject	Lithium Carbonate	Unknown	900 mg	Oral
Subject	Lithium Carbonate	Unknown	1200 mg	Oral

Indications